Products & Pipeline

One platform. A growing pipeline of therapeutics.

From our lead orthobiologic available today to a growing portfolio in development, every product is drawn from the same equine blood donation and the same manufacturing process.

Available Now

✓ In clinical useEquineIntra-synovial

BIO-PLY™

An off-the-shelf, platelet-derived orthobiologic that dampens inflammation, drives tissue repair, and helps fight joint infection. A long-term solution, not a short-term band-aid.

Triple
action
1 vial
no prep
FDA-CVM
innovation prog.
Vials of BIO-PLY, a platelet-derived orthobiologic

The Q-Biologics™ Platform

Same process, expanding portfolio.

BIO-PLY™ uses roughly 6% of every equine blood donation. The other 94% (plasma proteins, white blood cells, and more) feeds a growing portfolio of biologics, all from the same donation and the same manufacturing process. We can't share everything about our upcoming programs yet, but here's what each one is and how far along it is.

Program & source
BIO-PLY™
Platelets · ~6% of donation
Orthobiologic for equine musculoskeletal injury & joint infection, our lead product.
Available · FDA journey underway
Development stage: FDA Journey (stage 4 of 5)
NAP-X
White blood cells · ~1% of donation
White-blood-cell-derived biologic, a further therapeutic fraction.
Preclinical development
Development stage: Preclinical (stage 2 of 5)
Additional fractions
Remaining fractions of the donation
Additional fractions remain available, the opportunity for future pipeline development.
Exploratory
Development stage: Discovery (stage 1 of 5)

Development stages and timing are indicative and subject to change. Contact us for the current status of any program.

Our journey

Key milestones, 2022–2026.

From founding to first product — the milestones that brought BIO-PLY™ to market and built the pipeline behind it.

2022
  • Company founded
2023
  • INAD @ FDA-CVM open
  • Donor herd established
  • Clinical trials started
2024
  • Clinical trials continue
  • New pipeline product exploration
  • Manufacturing facility upfit
2025
  • Clinical trial conclusion
  • NAP-X preclinical development started
2026
  • MUMS designation received
  • BIO-PLY™ manufacturing scaleup

Stay in the loop

Sign up for our newsletter.

Be the first to hear about new products, clinical trials, events we're attending, company milestones, and more — delivered straight to your inbox.

Prefer social? Follow us on LinkedIn — we announce new products, clinical trials, events, and milestones there too.

Get started

Interested in BIO-PLY™?

Register to receive more information about using BIO-PLY™ in your clinic.

Register

Stay in the loop

Join our newsletter

New products, clinical trials, events, and milestones — announced by email and on our social channels.

Subscribe

Everything else

Get in touch

Trials, partnerships, investment, or press, we'd love to hear from you.

Contact us